Literature DB >> 26135666

ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW.

Yuya Yoshimoto1, Koji Kono, Yoshiyuki Suzuki.   

Abstract

An anti-tumor immune response is one of the most important factors that can determine treatment response and prognosis of cancer patients. Recent studies have demonstrated that radiotherapy can activate tumor-specific immune responses and that these responses contribute to the therapeutic efficacy. However, the exact mechanisms underlying the radiation-induced immune responses remain unclear. Better understanding of the mechanisms could facilitate the application of immune-activating radiotherapy and provide new treatment strategies. We previously demonstrated that tumor-specific T cell responses could be induced in esophageal cancer patients during and after chemoradiotherapy. Furthermore, in a mouse model, immune responses played an important role in determining the local and systemic therapeutic efficacy of radiotherapy that could be augmented by the immune checkpoint blockade. In this review, radiotherapy-induced immune responses, the mechanisms underlying the induction of those responses, and a practical application of the therapy are discussed.

Entities:  

Mesh:

Year:  2015        PMID: 26135666      PMCID: PMC5131595          DOI: 10.5387/fms.2015-6

Source DB:  PubMed          Journal:  Fukushima J Med Sci        ISSN: 0016-2590


  76 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

3.  Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis.

Authors:  K Ohba; K Omagari; T Nakamura; N Ikuno; S Saeki; I Matsuo; H Kinoshita; J Masuda; H Hazama; I Sakamoto; S Kohno
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 4.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 5.  Immune infiltration in human tumors: a prognostic factor that should not be ignored.

Authors:  F Pagès; J Galon; M-C Dieu-Nosjean; E Tartour; C Sautès-Fridman; W-H Fridman
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

6.  Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Authors:  Aristotelis Bamias; Vasiliki Koutsoukou; Evangelos Terpos; Marinos L Tsiatas; Christina Liakos; Ourania Tsitsilonis; Alexandros Rodolakis; Zannis Voulgaris; G Vlahos; Theocharis Papageorgiou; G Papatheodoridis; A Archimandritis; A Antsaklis; M A Dimopoulos
Journal:  Gynecol Oncol       Date:  2007-11-26       Impact factor: 5.482

7.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors:  Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

8.  HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.

Authors:  Michiko Harao; Shinya Hirata; Atsushi Irie; Satoru Senju; Tetsuya Nakatsura; Hiroyuki Komori; Yoshiaki Ikuta; Kazunori Yokomine; Katsunori Imai; Mitsuhiro Inoue; Kumiko Harada; Takeshi Mori; Takuya Tsunoda; Shuichi Nakatsuru; Yataro Daigo; Hiroaki Nomori; Yusuke Nakamura; Hideo Baba; Yasuharu Nishimura
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

Review 10.  Trial Watch: Anticancer radioimmunotherapy.

Authors:  Erika Vacchelli; Ilio Vitale; Eric Tartour; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-03       Impact factor: 8.110

View more
  7 in total

Review 1.  Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.

Authors:  C Alberti
Journal:  G Chir       Date:  2017 Sep-Oct

2.  Elevated neutrophil-to-lymphocyte ratio is associated with nutritional impairment, immune suppression, resistance to S-1 plus cisplatin, and poor prognosis in patients with stage IV gastric cancer.

Authors:  Kenji Gonda; Masahiko Shibata; Yu Sato; Maria Washio; Hiroyuki Takeshita; Hirofumi Shigeta; Michikazu Ogura; Shinichi Oka; Shinich Sakuramoto
Journal:  Mol Clin Oncol       Date:  2017-10-04

3.  Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma.

Authors:  Yu Sato; Kenji Gonda; Maiko Harada; Yuki Tanisaka; Shin Arai; Yumi Mashimo; Hirotoshi Iwano; Hiroshi Sato; Shomei Ryozawa; Takao Takahashi; Shinichi Sakuramoto; Masahiko Shibata
Journal:  Biomed Rep       Date:  2017-06-07

Review 4.  Role of Mitochondria in Radiation Responses: Epigenetic, Metabolic, and Signaling Impacts.

Authors:  Dietrich Averbeck; Claire Rodriguez-Lafrasse
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

5.  Baseline FDG Uptake And Peripheral Lymphocyte-Monocyte Ratio For Predicting Chemoradiotherapy Response In Patients With Esophageal Squamous Cell Carcinoma.

Authors:  Chunsheng Wang; Kewei Zhao; Yong Huang; Li Ma; Yipeng Song; Minghuan Li
Journal:  Cancer Manag Res       Date:  2019-10-24       Impact factor: 3.989

Review 6.  Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer.

Authors:  Chao Cheng; Lingdun Zhuge; Xin Xiao; Siyuan Luan; Yong Yuan
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

7.  Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.

Authors:  Incheol Seo; Hye Won Lee; Sang Jun Byun; Jee Young Park; Hyeonji Min; Sung Hwan Lee; Ju-Seog Lee; Shin Kim; Sung Uk Bae
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.